HRP20140416T1 - Alkalna fosfataza koja je usmjerena na kosti, pribor i postupci uporabe - Google Patents

Alkalna fosfataza koja je usmjerena na kosti, pribor i postupci uporabe Download PDF

Info

Publication number
HRP20140416T1
HRP20140416T1 HRP20140416AT HRP20140416T HRP20140416T1 HR P20140416 T1 HRP20140416 T1 HR P20140416T1 HR P20140416A T HRP20140416A T HR P20140416AT HR P20140416 T HRP20140416 T HR P20140416T HR P20140416 T1 HRP20140416 T1 HR P20140416T1
Authority
HR
Croatia
Prior art keywords
alkaline phosphatase
amino acid
hpp
salp
cell
Prior art date
Application number
HRP20140416AT
Other languages
English (en)
Croatian (hr)
Inventor
Philippe Crine
Guy Boileau
Thomas P. Loisel
Isabelle Lemire
Pierre Leonard
Heft Robert
Hal Landy
Original Assignee
Alexion Pharma Holding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Holding filed Critical Alexion Pharma Holding
Publication of HRP20140416T1 publication Critical patent/HRP20140416T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
HRP20140416AT 2007-05-11 2014-05-08 Alkalna fosfataza koja je usmjerena na kosti, pribor i postupci uporabe HRP20140416T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
HRP20140416T1 true HRP20140416T1 (hr) 2014-06-20

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140416AT HRP20140416T1 (hr) 2007-05-11 2014-05-08 Alkalna fosfataza koja je usmjerena na kosti, pribor i postupci uporabe

Country Status (25)

Country Link
US (1) US20100297119A1 (enExample)
EP (3) EP2662448B1 (enExample)
JP (1) JP5732603B2 (enExample)
AT (1) ATE536413T1 (enExample)
AU (1) AU2008250945B2 (enExample)
BR (2) BRPI0811198B8 (enExample)
CA (1) CA2687001C (enExample)
CY (1) CY2016005I1 (enExample)
DE (1) DE202008018131U1 (enExample)
DK (3) DK2158319T3 (enExample)
ES (3) ES2380546T3 (enExample)
FR (1) FR16C0007I2 (enExample)
HR (1) HRP20140416T1 (enExample)
HU (2) HUE031655T2 (enExample)
IL (1) IL202057A0 (enExample)
LT (1) LTC2368999I2 (enExample)
LU (1) LU92976I2 (enExample)
ME (1) ME01828B (enExample)
NL (1) NL300798I1 (enExample)
NO (1) NO2016002I2 (enExample)
PL (3) PL2158319T4 (enExample)
PT (3) PT2368999E (enExample)
RS (1) RS53302B (enExample)
SI (2) SI2662448T1 (enExample)
WO (1) WO2008138131A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) * 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
AU2011245005A1 (en) * 2010-04-30 2012-11-22 Alexion Pharma Holding Methods, compositions, and kits for the treatment of matrix mineralization disorders
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) * 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014031646A2 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
PL3097189T3 (pl) 2014-01-24 2018-11-30 Am-Pharma B.V. Chimeryczne białka podobne do alkalicznej fosfatazy
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
MX394116B (es) 2015-07-24 2025-03-19 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
RU2745528C2 (ru) * 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) * 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
JP7613826B2 (ja) * 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
AU2017371182B2 (en) 2016-12-09 2024-03-28 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
CA3057502A1 (en) * 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド 糖タンパク質の製造
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症1型および関連状態を治療する方法
CA3137045A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
US12433938B2 (en) * 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12478662B2 (en) 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
WO2022051555A2 (en) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3263089A1 (en) * 2022-08-31 2024-03-07 Univ Utah Res Found GJA1-20K COMPOSITIONS AND METHODS FOR MITIGATING ISCHEMIC-REPERFUSION INJURY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル. グラハム,フランク 遺伝子治療のためのアデノウイルスベクター
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ,インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ES2284545T3 (es) 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
BRPI0512496A (pt) 2004-06-23 2008-03-04 Genzyme Corp processos e composições para o tratamento de doenças policìsticas
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
JP2008521575A (ja) 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法

Also Published As

Publication number Publication date
HK1162589A1 (en) 2012-08-31
IL202057A0 (en) 2011-08-01
BR122019000505B1 (pt) 2022-01-18
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
PL2368999T3 (pl) 2014-08-29
BRPI0811198A2 (pt) 2014-10-21
CY2016005I2 (el) 2016-08-31
NL300798I2 (enExample) 2016-03-16
BRPI0811198B1 (pt) 2021-03-09
DE202008018131U1 (de) 2011-12-30
CA2687001A1 (en) 2008-11-20
HK1141047A1 (en) 2010-10-29
PL2662448T3 (pl) 2017-07-31
EP2368999A1 (en) 2011-09-28
NO2016002I1 (no) 2016-02-02
RS53302B (sr) 2014-08-29
DK2368999T3 (da) 2014-05-26
SI2368999T1 (sl) 2014-07-31
WO2008138131A4 (en) 2008-12-31
NO2016002I2 (no) 2016-02-02
WO2008138131A9 (en) 2009-08-06
PL2158319T4 (pl) 2016-04-29
DK2158319T3 (da) 2012-03-19
ME01828B (me) 2014-12-20
NL300798I1 (enExample) 2016-03-16
EP2158319A1 (en) 2010-03-03
ES2471915T3 (es) 2014-06-27
HUS1600005I1 (hu) 2016-02-29
JP2010526543A (ja) 2010-08-05
FR16C0007I1 (enExample) 2016-04-15
HK1191372A1 (en) 2014-07-25
AU2008250945A1 (en) 2008-11-20
BRPI0811198B8 (pt) 2021-05-25
US20100297119A1 (en) 2010-11-25
LTPA2016004I1 (lt) 2016-02-25
EP2158319A4 (en) 2010-07-21
ES2380546T3 (es) 2012-05-16
BR122019000505A2 (pt) 2021-12-14
LU92976I2 (en) 2016-04-11
PL2158319T3 (pl) 2012-05-31
PT2662448T (pt) 2017-03-29
SI2662448T1 (sl) 2017-05-31
DK2662448T3 (en) 2017-03-20
EP2662448B1 (en) 2016-12-21
PT2158319E (pt) 2012-03-06
LTC2368999I2 (lt) 2017-09-25
EP2368999B1 (en) 2014-03-12
ES2619332T3 (es) 2017-06-26
WO2008138131A1 (en) 2008-11-20
PT2368999E (pt) 2014-05-26
AU2008250945A2 (en) 2009-12-24
CA2687001C (en) 2019-02-12
BRPI0811198A8 (pt) 2018-08-14
AU2008250945B2 (en) 2013-12-12
CY2016005I1 (el) 2016-08-31
ATE536413T1 (de) 2011-12-15
JP5732603B2 (ja) 2015-06-10
FR16C0007I2 (fr) 2017-01-27
EP2158319B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
HRP20140416T1 (hr) Alkalna fosfataza koja je usmjerena na kosti, pribor i postupci uporabe
JP2010526543A5 (enExample)
Hannallah et al. Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model
Uludag et al. Delivery systems for BMPs: factors contributing to protein retention at an application site
AU2002320157B2 (en) Antibodies to OPGL
ES2599103T3 (es) Producción de anticuerpos anti-beta-amiloide
US6310040B1 (en) Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
ES2618832T3 (es) Composición TNFR-FC estabilizada que comprende arginina
ES2254403T3 (es) Produccion de muteinas recombinantes de factor de coagulacion sanguinea viii en lineas de celulas humanas.
ES2798758T3 (es) Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
ES2342397T3 (es) Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
RU2010114713A (ru) Нейроэндокринные факторы для лечения дегенеративных заболеваний
ES2405273T3 (es) Polipéptido coestimulador B7-H5
CN104178491A (zh) 治疗性人抗-il-1r1单克隆抗体
AU2020226893A1 (en) Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN105829349A (zh) 肽嵌合抗原受体t细胞开关和其用途
US20210061880A1 (en) Single-chain cd27-receptor agonist proteins
JP2025526742A (ja) ステロール系イオン化脂質及びそれを含む脂質ナノ粒子
CA3002588C (en) Single-chain cd137-receptor agonist proteins
Sun et al. Transplantation of betatrophin-expressing adipose-derived mesenchymal stem cells induces β-cell proliferation in diabetic mice
CA3002587A1 (en) Single-chain light receptor agonist proteins
TW202208437A (zh) 包含抗lag-3抗體及il-2的融合蛋白及其用途
US20180244753A1 (en) Single-chain tl1a receptor agonist proteins
US20240383952A1 (en) Recombinant variants of r-spondin proteins and their use
KR20220103695A (ko) 근육 위축을 치료하기 위한 펩티드